ENOV · Enovis Corporation

Enovis Corporation reported first quarter 2026 results that showed solid execution and continued progress in its innovation-led strategy. Net sales of $589 million grew 5% on a reported basis and 3% organically, driven by strong performance in the Reconstructive segment, which grew 11% reported and 6% organic. The Prevention & Recovery segment was flat reported and up 1% organic. The company reported a GAAP net loss of $8 million, or 1.4% of sales, a significant improvement from the $55.7 million loss in the prior year quarter, primarily due to higher gross margins (62.0% vs 59.5%) and lower restructuring charges. On an adjusted basis, net income from continuing operations was $51.6 million, or $0.89 per diluted share, up from $37.3 million and $0.65 in Q1 2025, reflecting operational leverage and cost discipline. Adjusted EBITDA reached $104 million, or 17.6% of sales. Management highlighted contributions from recent product launches and stable end markets, while acknowledging a dynamic macroeconomic and geopolitical environment. The company reaffirmed its full-year 2026 guidance: revenue of $2.31-2.37 billion (4-6% organic growth), adjusted EBITDA of $425-435 million, adjusted EPS of $3.52-3.73, and free cash flow conversion of 25% or higher. The earnings release and conference call provide investors with confidence in the company's ability to navigate near-term uncertainty while investing in long-term growth.